Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine
Monica Fung(University of California, San Francisco), Sophia Koo(Dana-Farber Brigham Cancer Center), Arnold S. Freedman(Otsuka (Japan)), Xiangmei Gu(Brigham and Women's Hospital), Eric D. Jacobsen(Dana-Farber Cancer Institute), Dimitrios Farmakiotis(Brown University), Daniel Prestes(Brigham and Women's Hospital), Paul L. Nguyen(Beth Israel Deaconess Medical Center)
Cited by 64
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
COVID-19 in Immunocompromised Hosts: What We Know So Far
|Clinical Infectious Diseases|2020|568
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468